Neuromuscular Symptom and Disability Score (NSS)
Click the buttons provided below to view information contained in a specific part of this record:
|
General Information
|
| Objectives |
|
14 activities of daily life can be evaluated by using the Neuromuscular Symptom and Disability Functional Score (NSS).
|
|
| Category of Outcome Measure |
Impairment
Participation / Handicap
Quality of Life
|
|
| Disease Type |
| |
Used |
Validated |
| Anterior Horn Cell Disease |
X |
|
| Peripheral Nerve |
X |
|
| Neuromuscular Junction |
X |
|
| Muscle |
X |
|
|
|
| Chronology of Development |
|
The questionnaire is based on the scores described in the study by Dalakas et al: Treatment of inclusion body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997 48: 712–716. Normal values for handgrip strenth have been obtained in a study with 300 normal control persons. Mean value (in kg) is calculated after 3 runs for each hand.
|
|
| Recall Period |
|
Before and After Treatment
|
|
| Mode of Assessment |
Administered by trained evaluator
|
|
| Age Group |
Adolescents (12 to 15 Years)
Adults (16 Years and Over)
|
|
| Languages |
| |
Original |
Definitive Validated Translation |
Informal Translation |
| English UK |
X |
|
|
| German |
|
|
X |
|
|
| Conditions of Use and Contact Information |
| Organisation Name |
|
Friedrich-Baur-Institute, Dept. of Neurology, Ludwig-Maximilians-University of Munich, Germany
|
|
| Postal Address |
|
Ziemssenstr 1, München, 80336, Germany (PH: 498951607400)
|
|
|
|
|
Questionnaire/Scale
|
| Domain Name / Number of Items |
|
exhaustion following slight strain
|
|
raising to a sitting position
|
|
exhaustion following distinct strain
|
|
putting on socks and shoes
|
|
| Additional Format Information |
|
|
| Total Score |
Yes - total score is calculated.
|
|
| Total Score - Range/Direction |
|
0= severe disability, 42= no disability (For each question a score between 0 and 3 is allocated. 0=severe disability, 1=moderate disability, 2=slight disability, 3=no disability. Scores are then summed up.)
|
|
| Sub-Score |
No - sub-score is not calculated.
|
|
| Sub-Score Range/Direction |
|
|
|
|
Reference 1
|
| Reference Details |
|
Soueidan SA.; Dalakas MC.; (1993) Treatment of inclusion body myositis with high-dose intravenous immunoglobulin, Neurology, Vol 43, pp 876-879
|
|
|
|
|
Reference 2
|
| Reference Details |
|
Dalakas MC.; Sonies B.; Dambrosia J.; Sekul E.; Cupler E.; Sivakumar K.; (1997) Treatment of inclusion body myositis with IVIg: a double-blind, placebo-controlled study, Neurology, Vol 48,pp 712-716
|
|
|
|
|
Reference 3
|
| Reference Details |
|
Walter MC.; Lochmüller H.; Toepfer M.; Schlotter B.; Reilich P.; Schröder M.; Müller-Felber W.; Pongratz D.; (2000) High-dose immunoglobulin therapy (IVIG) in inclusion body myositis (IBM): A double-blind, placebo-controlled study, J of Neurology, Vol 247, pp 22-28
|
|
|
|
|
Reference 4
|
| Reference Details |
|
Walter MC.; Lochmüller H.; Reilich P.; Klopstock Th.; Huber R.; Hartard M.; Hennig M.; Pongratz D.; Müller-Felber W.; (2000) Creatine Monohydrate in Muscular Dystrophies: A Double-Blind, Placebo-Controlled Clinical Study, Neurology, Vol 54, pp 1848-1850
|
|
|
|
|
Reference 5
|
| Reference Details |
|
Walter MC.; Reilich P.; Lochmüller H.; Kohnen R.; Schlotter B.; Hautmann H.; Dunkl E.; Pongratz D.; Müller-Felber W.; (2002) Creatine Monohydrate in Myotonic Dystrophy - a Double-Blind, Placebo-Controlled Clinical Study, J of Neurology, Vol 249, pp 1717-1722
|
|
|
|
